Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2003
11/13/2003WO2003092683A1 Epothilone derivative for the treatment of hepatoma and other cancer diseases
11/13/2003WO2003092682A1 Zonisamide use in obesity and eating disorders
11/13/2003WO2003092680A1 New surfactant-based formulation containing triclabendazole
11/13/2003WO2003092676A1 Compositions and methods for preventing abuse of orally administered medications
11/13/2003WO2003092674A1 Prenatal multivitamin/multimineral supplement
11/13/2003WO2003092672A1 Method of inhibiting rejection of transplanted material
11/13/2003WO2003092667A1 Composition for treating cancer containing n,n-dimethylphytosphingosine
11/13/2003WO2003092654A1 Formulations limiting spread of pulmonary infections
11/13/2003WO2003092652A1 Warming and nonirritating anhydrous lubricant compositions
11/13/2003WO2003092651A1 Warming and nonirritating lubricant compositions
11/13/2003WO2003092650A1 Warming and nonirritating lubricant antifungal gel compositions
11/13/2003WO2003092647A2 Transport system in biological systems
11/13/2003WO2003092641A1 Topical glycopyrrolate product
11/13/2003WO2003092625A2 Carvedilol formulations
11/13/2003WO2003092624A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics
11/13/2003WO2003092623A2 Calicheamicin derivative-carrier conjugates
11/13/2003WO2003092621A2 Composition and method for dermatological treatment
11/13/2003WO2003092613A2 Catechin multimers as therapeutic drug delivery agents
11/13/2003WO2003092610A2 Methods of using cytokine antagonists to treat hiv infection and aids
11/13/2003WO2003092603A2 Composition and method for reducing post-prandial blood glucose
11/13/2003WO2003092589A2 Salt solution for colon cleansing
11/13/2003WO2003092584A2 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
11/13/2003WO2003092580A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003WO2003092542A2 Injectable chondrocyte implant
11/13/2003WO2003092468A2 Biomatrix structural containment and fixation systems and methods of use thereof
11/13/2003WO2003072090A3 Use of tyrosine kinase inhibitors for treating cns disorders
11/13/2003WO2003068968A3 Mutated gene coding for a lat protein and the biological applications thereof
11/13/2003WO2003061365A3 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
11/13/2003WO2003059354A3 Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
11/13/2003WO2003057165A3 COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
11/13/2003WO2003053966A3 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
11/13/2003WO2003041563A3 Neurotransmitter balance chemotherapy
11/13/2003WO2003040691A3 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
11/13/2003WO2003033654A3 Direct targeting binding proteins
11/13/2003WO2003033653A3 Affinity enhancement agents
11/13/2003WO2003032948A3 Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
11/13/2003WO2003032897A3 Azabicyclic compounds for the treatment of fibromyalgia syndrome
11/13/2003WO2003030944A3 Inhibition of stat-1
11/13/2003WO2003028536A3 Methods for diagnosing and treating heart disease
11/13/2003WO2003027316A3 Methods of using 33751, a human potassium channel family member
11/13/2003WO2003022360A3 Thermotherapy via targeted delivery of nanoscale magnetic particles
11/13/2003WO2003022215A3 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
11/13/2003WO2003020262A3 Use of polyunsaturated fatty acids for intra-arterial injection for selectively occluding blood supplies to neoplasias
11/13/2003WO2003018059A3 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
11/13/2003WO2003015703A3 Compositions and methods relating to novel benzodiazepine compounds and targets thereof
11/13/2003WO2003013432A3 Methods of use for novel sulfur containing organic nitrate compounds
11/13/2003WO2003009778A3 Methods and devices for delivery of therapeutic capable agents with variable release profile
11/13/2003WO2003002755A3 Glaucoma treatments with reduced hyperpigmentation
11/13/2003WO2003000889A3 Identification of ses-1 and the uses of the same
11/13/2003WO2003000117A3 Detection and treatment of prostate cancer
11/13/2003WO2002102984A3 Hdac9 polypeptides and polynucleotides and uses thereof
11/13/2003WO2002099115A3 Nucleic acid-associated proteins
11/13/2003WO2002092831A3 Method for identifying ligands for g protein coupled receptors
11/13/2003WO2002072888A3 Polymorphisms in the human cmoat gene and uses thereof
11/13/2003WO2002072031A3 Substituted tetracycline compounds as synergistic antifungal agents
11/13/2003WO2002066681A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
11/13/2003WO2002048715A3 Inflammatory markers for detection and prevention of diabetes mellitus
11/13/2003WO2002032874A8 Substituted heterocyclic compounds for treating multidrug resistance
11/13/2003US20030212145 Parkinson's disease; cognition activators; central nervous system disorders
11/13/2003US20030212138 Synergistic mixture; analgesics, antiinflammatory agents, cardiovascular disorders, anticancer agents
11/13/2003US20030212137 Administering a thyroid hormone receptor beta agonist and fibrate to lower triglyceride levels in blood
11/13/2003US20030212127 Method of treating actinic keratosis
11/13/2003US20030212125 Topical applying; skin disorders; antiinflammatory agents
11/13/2003US20030212119 Novel glucagon receptor antagonists/inverse agonists
11/13/2003US20030212109 Central nervous system disorders; psychological disorders
11/13/2003US20030212107 R-reliprodil for treating glaucoma
11/13/2003US20030212104 Treatment of diabetes and diabetic complications with NHE-1 inhibitors
11/13/2003US20030212088 Methods and compositions for treating, preventing or delaying onset of a neoplasm
11/13/2003US20030212083 Pemetrexed, antioxidant of monothioglycerol, l-cysteine or thioglycolic acid and excipient; anticancer agents
11/13/2003US20030212082 Controlling neovascularization; angiogenesis inhibitors; therapy for strokes, cardiovascular disorders; antitumor agents; antidiabetic agents; antiarthritic agents; psoriasis
11/13/2003US20030212080 Adenosine A2a receptor antagonists
11/13/2003US20030212077 Methods and compositions for treating tinea versicolor using combinations of retinoids and certain antifungals
11/13/2003US20030212075 Inhalation aerosol comprising tiotropium salt and propellant gas; respiratory system disorders
11/13/2003US20030212070 Dietetics; cardiovascular disorders; hypotensive agents; psychological disorders
11/13/2003US20030212062 Morpholinone and morpholine derivatives and uses thereof
11/13/2003US20030212059 Adenosine A2a receptor antagonists
11/13/2003US20030212048 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
11/13/2003US20030212044 Treatment of HIV
11/13/2003US20030212038 Anticancer agents; side effect reduction; synergistic mixture of antifolic acid and reducing methylmalonic acid concentration
11/13/2003US20030212037 Use of bvdu for inhibiting the growth of hyperproliferative cells
11/13/2003US20030212036 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory heptitis
11/13/2003US20030212028 Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
11/13/2003US20030212026 Induce immunology response
11/13/2003US20030212008 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
11/13/2003US20030212004 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
11/13/2003US20030211995 Therapy for drug resistance bacteria
11/13/2003US20030211993 Control cell proliferation, cell differentiation; culture product
11/13/2003US20030211967 Method for selectively inhibiting ghrelin action
11/13/2003US20030211964 Method of inhibiting pathogenicity of infectious agents
11/13/2003US20030211613 Methods of altering calcium transport
11/13/2003US20030211607 Antisense modulation of survivin expression
11/13/2003US20030211592 Methods of terminal sterilization of biological products
11/13/2003US20030211577 Novel G protein-coupled receptor, GAVE7
11/13/2003US20030211563 Human testis specific serine/threonine kinase 1 & 2
11/13/2003US20030211559 Comprises composition for identifying therapeutic agents that inhibit proteolytic processing of amyloid precursor protein; treating nervous system disorders
11/13/2003US20030211545 Using enzyme inhibitors to treat neuropsychological disorders such as schizophrenia and bipolar disorder; neuroleptic agents
11/13/2003US20030211542 Assays and methods of diagnosis and treatment based on use of sodium channels as targets for amyloid beta or its aggregates
11/13/2003US20030211540 Treatment of insulin resistance
11/13/2003US20030211529 Human Eag2
11/13/2003US20030211515 Comprises nucleotide sequences coding matrix protein for diagnosing and treating cancer
1 ... 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 ... 1151